PercuSense is running an ambulatory diabetes study which will be shared soon.
Public source
Publisher name
Public post
We've started our first-in-human ICU study: lactate, tissue oxygen, glucose and ketone, continuously, from one probe. This is the first patient trace we've shared. We'd…
Company
PercuSense
Intelligent biosensors to power the future of healthcare
- Industry
- Medical Device
- Location
- Valencia, US
- Company size
- 11–50 employees
About PercuSense
PercuSense’s continuous multi-analyte sensor system combines monitoring of multiple biosensors with knowledge of how diseases and illness progress to intelligently and proactively recommend treatment.
See moreLatest activity
Latest activity from PercuSense
3 signals
Research & Knowledge
PercuSense conducted a recently started ICU study where a PercuSense continuous metabolic sensor was placed into a patient six hours after an out-of-hospital cardiac arrest.
Research & Knowledge
PercuSense started its first-in-human ICU study using lactate, tissue oxygen, glucose, and ketone continuously from one probe.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
PharmaSens AG
PharmaSens AG completed the data collection for its SMART02 clinical study evaluating the patch pump integrated with SiBionics Continuous Glucose Monitoring technology.
Research & Knowledge
Podimetrics
Podimetrics published an eBook titled Breaking Barriers: Combatting Diabetic Amputations in Communities of Color to offer strategies and best practices for healthcare providers, patients, and health plans.
Research & Knowledge
FiberSense
FiberSense received feedback from Odelle Technology regarding the planned expansion of continuous glucose monitoring into professional care.
Research & Knowledge
IDTechEx
IDTechEx published the report Diabetes Management Technologies 2027-2037: Markets, Players, and Forecasts discussing the race to create a fully closed-loop insulin pump.
Research & Knowledge
Aqua Medical